Biological Anti-Infective Medicines LLC develops vaccines for antibiotic-resistant conditions. The company was founded by Brad Spellberg, whose research focuses on the problems of increasing drug resistance and decreasing new antibiotics. His laboratory research has focused on developing a vaccine that targets the bacterium Staphylococcus aureus and the fungus Candida; the vaccine is undergoing clinical development. Dr. Spellberg is currently working on the immunology, vaccinology, and host defense against highly resistant Gram negative bacilli, including Acinetobacter and carbapenem-resistant Enterobacteriaceae infections. The company is particularly focused on vaccines targeting Acinetobacter.
